| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
J Am Dent Assoc, Vol 137, No 8, 1144-1150.
© 2006 American Dental Association |  |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASSOCIATION REPORT |
Expert panel recommendations
Background. In light of the uncertainty surrounding the incidence of bisphosphonate-associated osteonecrosis of the jaw (BON) and concomitant risk factors, dentists have questioned how to manage the care of patients receiving oral bisphosphonate therapy. Expert panelists were selected by the American Dental Association Council on Scientific Affairs on the basis of their expertise in the relevant subject matter and on their respective dental or medical specialties, and the panel was tasked with developing guidance for dentists treating these patients.
Methods. There are no data from clinical trials evaluating dental management of the care of patients receiving oral bisphosphonate therapy and, therefore, these recommendations are based on a thorough review of the available literature relating to bisphosphonate use and osteonecrosis of the jaw. After reviewing the literature, the panel developed these recommendations based on their expert opinion.
Results. These panel recommendations focus on conservative surgical procedures, proper sterile technique, appropriate use of oral disinfectants and the principles of effective antibiotic therapy.
Conclusions. The recommendations are a resource for dentists to use in their practice, in addition to the dentist’s own professional judgment, the information available in the dental and medical literature, and information from the patient’s treating physician. The recommendations must be balanced with the practitioner’s professional judgment and the individual patient’s preferences and needs.
This article has been cited by other articles:
|
|
 |
|
  A. Badros, E. Terpos, E. Katodritou, O. Goloubeva, E. Kastritis, E. Verrou, K. Zervas, M. R. Baer, T. Meiller, and M. A. Dimopoulos Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma J. Clin. Oncol., December 20, 2008; 26(36): 5904 - 5909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. CAREY and L. PALOMO Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk? Cleveland Clinic Journal of Medicine, December 1, 2008; 75(12): 871 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Dimopoulos, E. Kastritis, C. Bamia, I. Melakopoulos, D. Gika, M. Roussou, M. Migkou, E. Eleftherakis-Papaiakovou, D. Christoulas, E. Terpos, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann. Onc., August 9, 2008; (2008) mdn554v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mariotti Bisphosphonates and Osteonecrosis of the Jaws J Dent Educ., August 1, 2008; 72(8): 919 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Estilo, C. H. Van Poznak, T. Wiliams, G. C. Bohle, P. T. Lwin, Q. Zhou, E. R. Riedel, D. L. Carlson, H. Schoder, A. Farooki, et al. Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy Oncologist, August 1, 2008; 13(8): 911 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. G. Shenker and A. S. M. Jawad Bisphosphonates and osteonecrosis of the jaw Rheumatology, July 1, 2007; 46(7): 1049 - 1051. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Mayes Review of Postmenopausal Osteoporosis Pharmacotherapy Nutr Clin Pract, June 1, 2007; 22(3): 276 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Compston Treatments for Osteoporosis -- Looking beyond the HORIZON N. Engl. J. Med., May 3, 2007; 356(18): 1878 - 1880. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
